Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.
Ricardo G AlvimPetrina GeorgalaLucas Mendes NogueiraAlexander J SommaKaran NagarJasmine ThomasLaura AlvimAmelia RiegelChristopher HughesJie ChenAugusto B ReisSouhil LebdaiAvigdor ScherzSteven ZanganehRui GardnerKwanghee KimJonathan A ColemanPublished in: Molecules (Basel, Switzerland) (2021)
Our findings suggest that VTP synergizes with PD-1 blockade and OX40 agonist to promote strong antitumor immune responses, yielding therapeutic efficacy in an animal model of urothelial cancer.